Last reviewed · How we verify
PROPANTHELINE BROMIDE
PROPANTHELINE BROMIDE is a drug. It is currently FDA-approved (first approved 1953).
Propantheline bromide is a small molecule that acts as a muscarinic acetylcholine receptor M3 antagonist. It has been studied in clinical trials for conditions such as urinary calculus and overactive bladder associated with HTLV-1.
At a glance
| Generic name | PROPANTHELINE BROMIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
Common side effects
Key clinical trials
- A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder (PHASE1)
- Compare the Therapeutic Effect Treated With Tamsulosin and Progesterone After ESWL( Extra Corporeal Shock Wave Lithotripsy) in Urinary Calculus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PROPANTHELINE BROMIDE CI brief — competitive landscape report
- PROPANTHELINE BROMIDE updates RSS · CI watch RSS
Frequently asked questions about PROPANTHELINE BROMIDE
What is PROPANTHELINE BROMIDE?
When was PROPANTHELINE BROMIDE approved?
What development phase is PROPANTHELINE BROMIDE in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing